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Abstract
Background: The aim of this research was to evaluate the economic outcomes of radiotherapy (RT), temozolomide (TMZ)
and nitrosourea (NT) strategies for glioblastoma patients with different prognostic factors.
Methodology/Principal Findings: A Markov model was developed to track monthly patient transitions. Transition
probabilities and utilities were derived primarily from published reports. Costs were estimated from the perspective of the
Chinese healthcare system. The survival data with different prognostic factors were simulated using Weibull survival models.
Costs over a 5-year period and quality-adjusted life years (QALYs) were estimated. Probabilistic sensitivity and one-way
analyses were performed. The baseline analysis in the overall cohort showed that the TMZ strategy increased the cost and
QALY relative to the RT strategy by $25,328.4 and 0.29, respectively; and the TMZ strategy increased the cost and QALY
relative to the NT strategy by $23,906.5 and 0.25, respectively. Therefore, the incremental cost effectiveness ratio (ICER) per
additional QALY of the TMZ strategy, relative to the RT strategy and the NT strategy, amounts to $87,940.6 and $94,968.3,
respectively. Subgroups with more favorable prognostic factors achieved more health benefits with improved ICERs.
Probabilistic sensitivity analyses confirmed that the TMZ strategy was not cost-effective. In general, the results were most
sensitive to the cost of TMZ, which indicates that better outcomes could be achieved by decreasing the cost of TMZ.
Conclusions/Significance: In health resource-limited settings, TMZ is not a cost-effective option for glioblastoma patients.
Selecting patients with more favorable prognostic factors increases the likelihood of cost-effectiveness.
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Introduction
Glioblastoma (GBM) is the most common and most aggressive
malignant brain tumor, and it is associated with poor prognoses
[1]; The median survival for newly diagnosed GBM cases is less
than one year. Most patients will die within two years, and only
12% of patients survive for five years [2]. For newly diagnosed
GBM, the current standard of care includes surgical resection to
the extent feasible, followed by radiotherapy and adjuvant
chemotherapy. Nitrosourea agents are widely administered.
Numerous clinical trials have been conducted to investigate the
efficacy of adding various chemotherapeutic regimens to radio-
therapy [3]. No significant survival benefit was achieved in
randomized phase 3 trials testing the combined strategy of
nitrosourea-based adjuvant chemotherapy and radiotherapy
compared to a strategy involving radiotherapy alone, but in some
studies, more long-term survivors were observed in the combined
strategy. One meta-analysis based on 12 randomized trials
indicated a relatively small survival benefit for the combined
strategy over radiotherapy alone (i.e., the survival rate at two years
increased by 5%, from 15% to 20%) [4]. These results suggest that
adjuvant chemotherapy may have a role in the treatment of newly
diagnosed GBM. The unsatisfactory prognosis of GBM indicates a
clear medical need for new treatments.
Temozolomide (TMZ) is a new orally administered systemic
alkylating agent that crosses the blood-brain barrier (BBB) to exert
antitumor activity [5,6]. The European Organisation for Research
and Treatment of Cancer (EORTC) and the National Cancer
Institute of Canada (NCIC) Clinical Trials have demonstrated that
adjuvant TMZ with radiotherapy significantly prolonged the
median progression-free survival (hazard ratio: 0.56, 95% CI:
0.47–0.66; p,0.0001) and the overall survival (hazard ratio: 0.63,
95% CI: 0.53–0.75; p,0.0001) throughout 5 years of follow-up
compared to radiotherapy alone. Patients in some favorable
prognostic subgroups, such as those aged ,50 years and those
who are O
6-methylguanine-DNA methyltransferase (MGMT)
methylated, gained more survival benefits [7]. TMZ is currently
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countries. However, the substantial cost of TMZ restricts its
widespread use, especially in health resource-limited regions like
China. Nitrosourea agents, such as carmustine, lomustine and
nimustine, are still commonly prescribed for patients with glioma
because of their relatively lower costs compared to TMZ.
Economic studies analyzing the cost-effectiveness of TMZ plus
radiotherapy for the treatment of GBM, compared to strategies
involving nitrosourea agents and radiotherapy alone, are needed
in health resource-constrained settings. Given the obvious
differences in survival rates among prognostic subgroups, such
cost-effectiveness analysis should be performed to guide clinical
practice.
In this economic study, we investigated the 5-year economic
outcomes of three first-line strategies for newly diagnosed patients
with GBM in both overall and subgroup cohorts based on Chinese
clinical practice and recommendations: radiotherapy alone,
nitrosourea agents plus radiotherapy and TMZ plus radiotherapy.
The follow-up times of most clinical trials have not focused on the
5-year course of the disease despite the previously mentioned
paucity of head-to-head comparisons of different strategies. Thus,
mathematical modeling techniques must be used to provide
information for decision-making. The perspective of the Chinese
healthcare system was adopted to assist in determining the direct
economic value of the three different first-line strategies in newly
diagnosed GMB and to compare the strategies with different
willingness-to-pay thresholds per quality-adjusted life-year (QALY)
gains. The analysis excluded indirect societal costs (e.g., produc-
tivity or caregiver costs).
Methods
Analytical Overview
Using the R software package (version 2.13.1; R Development
Core Team, Vienna, Austria), a state-transition (Markov) model
for newly diagnosed GBM was developed to track the 5-year
disease course. We used this model to measure and compare the 5-
year direct medical costs and health outcomes for the different
first-line strategies for newly diagnosed GBM. The analysis was
conducted from the perspective of the Chinese healthcare system.
In the model, future costs and health outcomes were not
discounted because most survival outcomes among GBM patients
are shorter than 2 years.
Patients with different prognostic factors have significantly
different survival times. Because no detailed clinical information
was available, simulation methods were used to generate the
survival rates of patients with combinations of different risk factors.
In the current analysis, the prognostic factors that were included
were age (,50, 50–60 or .60 years), methylation status of the
MGMT promoter (methylated or unmethylated), surgery type
(complete resection, partial resection or biopsy) and treatment
strategy (radiotherapy alone, radiotherapy plus nitrosourea or
radiotherapy plus TMZ). The Markov model developed for the
study was used to analyze the cost-effective outcome for each risk
subgroup cohort.
Although new therapies for GBM have been evaluated in
clinical trials, the most commonly used first-line strategies (after
neurosurgery) are radiotherapy alone, radiotherapy plus nitroso-
urea, radiotherapy plus Gliadel Wafer and radiotherapy plus
TMZ [8,9]. Because the Gliadel Wafer is not supplied in the
Chinese market, this analysis evaluated and compared the costs
and effectiveness of the following three first-line strategies:
radiotherapy alone, radiotherapy plus nitrosourea, and radiother-
apy plus TMZ. Because no head-to-head clinical trials have
compared these three first-line strategies, an indirect comparison
was performed following a well-established approach [10].
Parameter inputs for the model were: transition probabilities
(which reflect the probabilities at each cycle of changing between
two health states); event proportions (which govern the ratios of
events); direct medical costs (which were estimated based on direct
health resource consumption); and health state utilities (which
project the health-related quality of life for discrete health states).
These data were derived from published studies or from local
health systems.
Cost-effectiveness ratios were measured to evaluate the
outcomes of the different strategies. The main health outcomes
were presented with respect to quality-adjusted life-years (QALY).
Cost were converted into US dollar (2011 exchange rate, $
1=CYN 6.50).The results are presented as an incremental cost-
effectiveness ratio (ICER).
Decision Model Structure
A Markov decision model was used to evaluate the 5-year
clinical and economic outcomes associated with GBM and its
treatment. The cost-effectiveness model for glioma consists of
three mutually exclusive health states: disease-free, disease
progression and death (Figure 1). In the Markov model, the cycle
length was one month, and the patients began in a disease-free
state. During each 1-month cycle, patients either remained in the
same health state (a recursive arrow) or progressed to a new health
state (a straight arrow).
A hypothetical cohort that was clinically similar to the GBM
patients in the EORTC-NCIC trial was entered in the model. The
hypothetical patients were aged 18–70 years and had newly
diagnosed and histologically proven GBM. The patients had a
WHO performance status of 0–2 and adequate hematologic,
renal, and hepatic functions. Following biopsy or surgical
resection, they would receive one of three competing treatment
strategies to manage their newly diagnosed GBM (first-line
therapy): 1) radiotherapy (RT strategy); 2) radiotherapy and
TMZ (TMZ strategy); or 3) radiotherapy and nitrosoureas (NT
strategy). When the disease progressed, the patients were treated
with a second-line therapy (i.e., surgery, chemotherapy, or a
combination of the two) or with the best supportive care (BSC).
The second-line chemotherapy strategy was assumed to involve
the PCV (procarbazine, lomustine, and vincristine) regime [11].
Clinical Data
Transition parameters and proportions were derived from
randomized clinical trials or meta-analyses whenever possible.
Two-parameter Weibull survival models were fitted to the data
extracted from the Kaplan–Meier survival PFS and OS curves
using R statistical software. Estimated scale and shape parameters
and their standard errors (SEs) are listed in Table S1.
PFS and OS survival data for RT and RT+TMZ were derived
from the clinical trials [7,12,13], whereas survival data for
RT+NT were derived from a meta-analysis reported by Stewart
et al. [4]. In the two studies, RT was a common control strategy
for newly diagnosed GBM, in contrast to RT+TMZ or RT+NT.
We assumed that the survival rates from these studies could be
compared because the baseline characteristics for the study cohorts
were almost identical. To minimize bias, we assumed that the
survival rates of RT in the EORTC-NCIC trial were also the
baseline in the comparison with RT+NT. We assumed that the
survival models for RT and RT+NT could be fitted by Weibull
proportional hazards models. As such, the shape parameters of
RT+NT were equal to those of RT from the EORTC-NCIC trial.
The hazard ratio (HR) between RT and RT+NT that was used to
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equation: HR6cRT (EORTC-NCIC). The HR values between the RT
and RT+NT treatment arms were derived from studies reported
by Stewart et al. [4]. We assumed that severe adverse events
(SAEs) did not change the risk of tumor progression. The
proportions of second-line therapy for progressed GMB were
derived from EORTC-NCIC [7]. We assumed that the second-
line treatment in the RT+NT strategy was similar to that in
RT+TMZ.
PFS data were absent for some subgroup cohorts. We assumed
that the ratios of the hazard rate between OS and PFS in the
overall cohort were equal to those of the subgroup cohorts at any
time. Therefore, the absent Weibull parameters for PFS in some
subgroup cohorts could be estimated by the following three steps:
first, with the Weibull hazard function, we calculated the ratios of
the hazard rate between OS and PFS at each cycle in the overall
cohort; second, the hazard rates for PFS in the subgroup cohorts
were calculated using the ratios (i.e., by multiplying the hazard
rates for OS in the matched subgroup cohorts); finally, the hazard
rates at each cycle were fitted with the Weibull hazard function to
estimate the shape and scale parameters.
Medical Costs and Utilities
The costs of each strategy (Table 1) were estimated from the
perspective of the healthcare system in China. In this analysis,
indirect costs were not included. Direct medical costs that were
considered in the model included first- and second-line medical
therapies, concomitant medication during therapy, the manage-
ment of treatment-related severe adverse events (SAEs) (grade 3–
4), routine follow-up, laboratory tests and BSC in terminally ill
patients.
The treatment costs were estimated according to the following
schedules: 1) Radiotherapy: using a linear accelerator, a total dose
of 60 Gy was delivered as the focal radiotherapy once daily at
2 Gy per fraction, 5 days/week; 2) TMZ: 75 mg/m
2 per day
during radiotherapy (concomitant chemotherapy), 4 weeks off, and
then six cycles of 150–200 mg/m
2 for 5 days every 28 days were
administered (adjuvant chemotherapy); 3) Nitrosoureas: nimustine
(ACNU) is a type of nitrosourea [14,15] that is widely prescribed
for GBM patients in China, so the cost of ACNU was used in the
model as the cost of nitrosourea ACNU dosed at 100 mg/m
2,
which was assumed to be administered intravenously once every 6
weeks until the tumor progressed. The PCV regime in the second-
line treatment was administered at 8-week intervals: lomustine
110 mg/m
2 taken orally on day 1, procarbazine 60 mg/m
2 taken
orally on days 8 to 21, and vincristine 1.4 mg/m
2 (maximal dose
2 mg) administered intravenously on days 8 and 29 [11]. To
estimate the dosages of the chemotherapeutic agents, we assumed
that a typical patient weighed 65 kg and had a height of 1.64 m,
resulting in a body surface area of 1.72 m
2 [16].
The EORTC-NCIC study showed that hematologic toxicity,
gastrointestinal toxicity and infection were the main SAEs in the
RT+TMZ combined strategy. Our model incorporated these
treatment-related SAEs. SAE (grade$3) management strategies
were estimated based on patient records in local hospitals (Table 1).
We assumed that the probabilities of the SAEs among the
subgroup cohorts were similar to those of the overall cohorts.
The utility values for the various discrete health states were
obtained from a previously published report [17] and are shown in
Table 2. We assumed that the utilities of patients in China and the
UK were equivalent. Because TMZ and nitrosoureas are both
alkylating agents, we assumed that their utilities in RT+NT were
equivalent to those in RT+TMZ. When the tumor progressed, the
utility value in the state of the progressed disease would decrease
by 0.02 per month.
Economic Analyses
All parameters, including rates, costs and utilities, were entered
into the model with a statistical distribution: lognormal distribu-
tions were assigned to all input costs; beta distributions were
assigned to the utilities, probabilities and proportions; and
bivariate normal distributions were assigned to all Weibull
parameters. Using these distributions, a probabilistic sensitivity
analysis (PSA) based on a Monte-Carlo simulation (1,000
simulations) was performed to evaluate the impact of uncertainty
across all of the parameters simultaneously. Following WHO
recommendations, we used 36 per capita GDP of China ($
11,034)/QALY and 36 per capita GDP of Shanghai City ($
38,376)/QALY as the threshold values [18]. Cost-effectiveness
plane acceptability curves were plotted based on the outcomes
projected from all 1,000 simulations, which estimated the
willingness to pay (WTP) threshold for an incremental unit of
effectiveness. The base-case analysis was run for 5 years, which
was nearly a life-time horizon. Finally, to identify key model input
parameters relating to the robustness of the results, one-way
sensitivity analyses were conducted over the ranges shown in
Tables S1, 1 and 2. The results are expressed as tornado charts.
Results
Validation of the Model
The base-case model compared the clinical outcomes to the
results from clinical phase 3 trials. The median OS time from the
trials, in addition to models for the overall cohort, and subgroups
differentiated by age, MGMT methylation status and surgery
status, are shown in Table 3. The model-estimated data were
controlled at the 95% CI of the clinical trial data. The median PFS
Figure 1. Markov diagram of health states and the possible transitions among them during each 1-month cycle.
doi:10.1371/journal.pone.0034588.g001
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by the status of MGMT methylation were also set at the 95% CI of
the trial data. This indicates that our method for estimating the
missing PFS time data was a practical solution. Overall, these
results validated the model.
Base Case Analysis
The base case cost-effectiveness results (Table 4) were based on
a 5-year time horizon. The model projected that TMZ resulted in
a QALY of 1.09 in the overall cohort, which represents an increase
of 0.29 QALYs over RT and an increase of 0.25 QALYs over NT.
In the subgroup analysis, the results indicate a tendency for
additional health benefits to be achieved for each treatment
strategy in the cohort groups with more favorable prognostic
factors. For example, the additional utilities gained by the RT, NT
and TMZ strategies in subgroups with MGMT methylated,
compared to subgroups with MGMT unmethylated, were 0.36,
0.48 and 0.6 QALYs, respectively.
Table 4 also shows the total direct costs in the overall cohort
and in the eight risk-score subgroups. In the overall cohort, the
total cost of the TMZ strategy was $ 32,562.4, followed by $
8,655.9 for the NT strategy and $ 7,234.0 for the RT strategy. The
TMZ strategy was the most expensive strategy. Subgroups with
more favorable prognostic factors incurred higher direct medical
costs. However, except in the partial resection and biopsy only
subgroup, the TMZ strategy resulted in lower ICERs with more
favorable prognostic factors compared to the RT and NT
strategies (Table 4). This indicates that patients with more
favorable prognostic factors would be more reasonable candidates
for the TMZ strategy. Regardless of whether the analysis focused
on the overall cohort or on one of the eight risk score subgroups,
no NT strategy was dominated by the TMZ strategy because of
the lower prices associated with the NT strategy (Figure 2).
Uncertainty Analyses
The one-way sensitivity analyses reveal that some model
parameters had a substantial impact on the net health benefit of
the TMZ strategy compared to the RT strategy. The most
influential parameter presented in the tornado graphs (Figure 3)
was the cost of TMZ per 100 mg dose. Changing the cost for
TMZ by an amount in a range from $ 128 to $ 256 had the effect
of significantly changing the net health benefit. At the lower cost of
TMZ, which resulted in a lower total cost for the TMZ strategy,
the net health benefit increased to 21.07 QALYs
(WTP=$11,034). A higher total cost for the TMZ strategy was
observed at a higher cost for the TMZ, with the net health benefit
decreasing to 22.29 QALYs. In this analysis, the patients were
assumed to have a body surface area of 1.72 m
2. This estimate was
determined using a range from 1.61 to 1.83 m
2. The body surface
area was thus determined to be the second most substantial effect
factor, leading to a change in the net health benefit from 22.15 to
22.53 QALYs. The other important effect factors of the model
were the utility of the PFS in TMZ adjuvant chemotherapy and
Table 1. Medical Resource Use and Costs Estimates ($, year 2009 values).
Parameter Median Cost ($) Range $) Description and Reference
Operation 5,150
1 3,680,6,600 The overall cost acquired from local hospitals
Biopsy 1,180
1 882,1,470 The overall cost acquired from local hospitals
Radiotherapy 100 per fraction 90,120 Local charge
Temozolomide Shanghai development and reformation commission
100 mg 156 140,171
20 mg 38 34,41
Nimustine 25 mg 57 51,62 Shanghai development and reformation commission
Second-line composite drug costs 125
{ per cycle 115,135 Local charge
Supportive care 735
* per cycle 480,1,060 Local charge
Routine follow-up of patients 90
{ per unit 70,120 Local charge
Serious adverse events
Hematologic toxicity 321
" 289,353 Local charge
Infection 588
" 529,647 Local charge
Gastrointestinal toxicity 263
" 236,289 Local charge
1Components of costs were drugs and medical consumables (68%), surgery (10%), examination (9%), ward treatment and nursing (6%), anesthesia (4%) and
accommodation and meals (3%).
{The cost included the chemotherapeutic agents (85%) and other adjuvant drugs (15%).
{The cost included the physician visit (1%), magnetic resonance imaging or computed tomographic scan (75%), other examinations and drugs (24%).
*The cost included caregiver (20%) and symptom-released drugs (80%).
"The cost included drugs and medical consumables (87%), ward treatment and nursing (7%), and accommodation and meals (6%).
doi:10.1371/journal.pone.0034588.t001
Table 2. Base-Case Utilities.
State Mean (range) Reference
Progression-free 0.8872 (0.525–1.0) [17]
Progression-free+RT 0.8239 (0.425–0.995) [17]
Progression-free+RT+TMZ 0.7426 (0.175–0.98) [17]
Progression-free+RT+NT 0.7426 (0.175–0.98) [17]
Progression-free+TMZ 0.7331 (0.175–0.99) [17]
Progression-free+NT 0.7331 (0.175–0.99) [17]
Progressed 0.7314 (0.125–0.995) [17]
doi:10.1371/journal.pone.0034588.t002
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Median OS times (months) Median PFS times (months)
Treatment arm Trial (95% CI) Model Difference Trial (95% CI) Model Difference
Overall survival
RT 12.1 (11.2–13.0) 11.7 20.4 5.0(4.2–5.5) 4.7 20.3
RT+TMZ 14.6 (13.2–16.8) 14.9 0.3 6.9(5.8–8.2) 7.4 0.5
MGMT methylated
RT 15.3 (13.0–20.9) 15.6 0.3 5.9 (5.3–7.7) 6.8 0.9
RT+TMZ 23.4 (18.6–32.8) 24.1 0.7 10.3 (6.5–14.0) 10.4 0.1
MGMT unmethylated
RT 11.8 (10.0–14.4) 11.6 20.2 4.4 (3.1–6.0) 4.0 20.4
RT+TMZ 12.6 (11.6–14.4) 12.9 0.3 5.3 (5.0–7.6) 5.3 0.0
Complete resection
RT 14.2 (12.1–16.1) 14.0 20.2 - 5.6 NA
RT+TMZ 18.8 (16.4–22.9) 18.0 20.8 - 8.7 NA
Partial resection
RT 11.7 (9.7–13.1) 11.6 20.1 - 4.6 NA
RT+TMZ 13.5 (11.9–16.4) 12.0 21.5 - 7.1 NA
Biopsy only
RT 7.8 (6.4–10.6) 7.8 0.0 - 3.6 NA
RT+TMZ 9.4 (7.5–13.6) 9.0 20.4 - 4.4 NA
Age ,50 years
RT 13.6 (11.6–15.6) 12.7 20.9 - 5.4 NA
RT+TMZ 17.4 (15.3–21.5) 15.1 22.3 - 9.5 NA
Age 50–60 years
RT 12.0 (10.0–14.2) 11.9 20.1 - 5.2 NA
RT+TMZ 14.6 (13.6–17.9) 13.8 20.8 - 6.4 NA
Age .60 years
RT 11.8 (10.4–12.7) 11.8 0.0 - 4.3 NA
RT+TMZ 10.9 (8.9–14.9) 10.4 20.5 - 6.1 NA
NA: not applicable.
doi:10.1371/journal.pone.0034588.t003
Table 4. Base Case Results for the Alternative Strategies for Cost, QALY Gained and ICER.
Cost ($) Utility (QALY) ICER
Cohort RT NT+RT TMZ+RT RT NT+RT TMZ+RT
TMZ+RT VS.
RT
TMZ+RT VS.
RT+NT
NT+RT VS.
RT
Overall cohort 7,234.0 8,655.9 32,562.4 0.80 0.84 1.09 87,940.6 94,968.3 39,185.1
Subgroups:
MGMT methylated 7,753.3 9,500.0 37,598.2 1.12 1.27 1.47 7,015.3 141,144.1 11,237.3
MGMT unmethylated 7,206.6 8,540.0 31,319.8 0.76 0.79 0.87 19,188.7 299,673.0 46,454.0
Complete resection 7,677.3 9,678.5 34,644.4 0.94 1.02 1.27 6,898.8 100,108.0 26,207.2
Partial resection 7,267.0 8,703.3 28,193.7 0.80 0.84 0.96 11,180.8 168,668.1 35,537.2
Biopsy only 6,074.1 6,855.1 25,598.8 0.57 0.61 0.73 10,741.1 157,802.5 23,883.3
Age ,50 years 7,672.3 9,900.1 29,351.4 0.87 0.97 1.16 6,125.4 103,010.5 20,995.6
Age 50,60 years 7,374.4 8,866.0 32,182.4 0.82 0.86 1.02 10,609.3 155,206.9 33,419.7
Age .60 years 6,990.5 8,261.0 26,388.8 0.78 0.79 0.86 21,434.9 279,507.5 120,317.5
doi:10.1371/journal.pone.0034588.t004
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factors, such as the costs of managing SAEs and incidences of
SAEs, had little impact (not shown in the tornado diagram).
The PSA comprising 1,000 simulations measured the probabil-
ities of meeting the ICER thresholds of $11,034 and $38,376 per
additional QALY for the TMZ strategy compared to RT and NT
strategies for GBM patients. The results are presented in Figure 4.
When the ICER threshold was $11,034, the probabilities of
achieving cost-effectiveness with the TMZ strategy relative to that
with the RT and NT strategies in the overall cohort and the 8 risk
score subgroups were all zero. When the threshold increased to the
point where there was a 50% probability of achieving cost
effectiveness in the overall cohort, the subgroups with MGMT
methylated, complete resection and age,50 years achieved
greater than 50% cost-effectiveness with the TMZ strategy
compared to the RT strategy, and the subgroups with complete
resection and age,50 years gained greater than 50% cost-
effectiveness with the TMZ strategy compared to the NT strategy.
The cost-effectiveness acceptability curves (CEACs) show the
preferred first-line strategies for GBM in the overall cohort and the
8 subgroups when a range of cost-per-QALY thresholds is taken
into account. The CEAC plot shows that when the threshold was
$11,034, the likelihood of achieving cost-effectiveness with the RT
strategy might be higher than the likelihood of achieving cost-
effectiveness with the TMZ and NT strategies in the overall cohort
and in 7 subgroups. In the subgroup with MGMT methylated
patients, the NT strategy achieved a similar probability of cost-
effectiveness as the RT strategy. When the threshold was $38,376,
the NT strategy achieved the maximum likelihood of cost-
effectiveness in the subgroups with MGMT methylated, complete
resection, partial resection, biopsy only, age,50 years and age
50,60 years (Figure 5).
Discussion
Since TMZ was introduced as a first-line treatment in newly
diagnosed GBM, survival rates and quality of life have both
improved. However, the widespread use of TMZ has resulted in a
dramatic increase in healthcare costs. An economic evaluation of
the recommended TMZ strategy as a first-line therapy in a health
resource–limited setting can help policy-makers, physicians and
patients to make the proper decisions. Using decision-analytic
modeling techniques, we estimated the cost-effectiveness of three
first-line GBM strategies in an overall cohort and in 8 subgroups
with different prognostic factors from the perspective of the
Chinese healthcare system over a 5-year period.
Our results suggest that the TMZ strategy as a first-line
treatment for GBM may possess significant advantages in relation
to health benefits. However, the gap between the costs of TMZ
and payment capacity in a health resource-limited setting may be
too great to allow the TMZ strategy to be recognized as the most
appropriate approach. In the overall cohort, the TMZ strategy
(when compared to the RT and NT strategies) revealed benefits
Figure 2. Analysis of the cost effectiveness of the first-line strategies for GBM in the overall cohort and the 8 subgroups. The x-axis
represents the undiscounted 5-year quality-adjusted life-years (QALYs) for each strategy, and the y-axis represents the total undiscounted 5-year costs
(in US dollars). The oblique line connects the RT strategy and the most cost-effective strategies; strategies above the straight lines were dominatedo r
extended dominated.
doi:10.1371/journal.pone.0034588.g002
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and $ 94,968.3, respectively. These costs are far greater than the
societal willingness-to-pay thresholds for each additional quality-
adjusted life-years gained ($11,034 and $38,376 for all of China
and Shanghai City, respectively). These higher ratios are largely
attributable to the high cost and the relatively limited survival
benefits associated with TMZ. The ICERs identified in other
health economic analyses from relatively health resource-rich
regions ranged from J37,000 per life-year gained to J42,840 per
QALY gained for the TMZ strategy compared with the RT
strategy [19,20,21]. These results indicate that the addition of
TMZ to radiotherapy in GBM patients is relatively inefficient in
economic terms. It was expected that a major cost reduction might
be achieved if the use of TMZ was restricted to those patients who
had a greater likelihood of benefiting from it [22]. Our subgroup
cohort analyses with three major prognostic factors indicated that
Figure 3. A tornado diagram of one-way uncertainty analyses in the overall cohort. The graph shows the effects of the variables on net
health benefit (in QALYs, with WTP=$11,034) between the RT and TMZ strategies. The width of the bars represents the range of the results when the
variables are changed, as shown in Tables 1, 2, 3. The vertical dotted line represents the base-case results. The vertical line represents the base-case
value for the net health benefit with WTP=$11,034. PFS: progression-free survival; OS: overall survival; HR: hazard ratio.
doi:10.1371/journal.pone.0034588.g003
Figure 4. The probabilistic results of the incremental cost-utility differences for GBM in the overall cohort and the 8 subgroups. The
TMZ strategy was compared to: (A) the RT strategy and (B) the NT strategy for a cohort of 1,000 GBM patients. The y-axis represents the incremental
costs. The x-axis represents the incremental QALYs gained. Each ellipse represents the 95% confidence interval ellipse of the probabilistic results. The
proportion of the ellipses found below the ICER threshold (the oblique lines) reflects the simulations in which the cost per additional QALY gained
with the TMZ strategy was below the ICER threshold.
doi:10.1371/journal.pone.0034588.g004
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in the eight subgroups, gradually decrease as the prognostic factors
become more favorable. However, no ICERs could achieve the
feasible affordability threshold for society in China or in Shanghai
City. Compared to the TMZ and NT strategies, the RT strategy
provided a higher probability of cost-effectiveness under the
Chinese threshold in the overall cohort and in almost all of the
subgroups. The NT strategy seemed to be a cost-effective option
under the threshold of Shanghai City for 6 subgroups when
compared to the TMZ and RT strategies. Different regions should
consider different therapies for GBM based on their capacities for
affording the costs. Chinese physicians and patients often face
dilemmas regarding the use of expensive therapies. The TMZ
strategy also faces this dilemma because it is an expensive
treatment option. To a certain extent, it might still be appropriate
to recommend the TMZ strategy for some subgroups with a lower
ICER for the TMZ strategy compared to the RT and NT
strategies. Overall, our results indicate that the strategy for treating
GBM should carefully consider the results of economic analysis to
optimize the allocation of health resources, especially in resource-
limited settings.
The one-way sensitivity analysis shows that the results of the
model were driven by certain key parameters (particularly the cost
of TMZ). As Figure 4 shows, when the cost of TMZ was increased
or decreased within the range of the upper and lower prices of
TMZ, the net health benefit increased or decreased dramatically.
The absolute value of the difference reached 1.22 QALYs. This
finding indicates that the pharmaceutical industry should adopt a
more prudent and conservative approach in its pricing [22]. At
present, a generic version of TMZ is being supplied for Chinese
patients at a price that is approximately half the price of the brand-
name TMZ drug. If the clinical efficacy of the generic drug is
equal to that of the brand-name drug, the cost-effectiveness of the
TMZ strategy will improve significantly. Because the dosages of
TMZ administered to the patients were calculated using the body
surface area, the body surface area was found to be the second
most influential factor. A higher body surface area resulted in a
higher dose of TMZ, which in turn increased the cost of the TMZ
strategy and ICERs compared to the RT strategy. Other
important influential factors include the utility of PFS in TMZ
adjuvant chemotherapy, the HR of PFS in the TMZ strategy
compared to the RT strategy and the utility of PFS in RT+TMZ
concomitant chemotherapy. Other factors, such as the probabil-
ities of SEAs and the costs of managing SEAs, did not significantly
affect the final results.
Several limitations of the current analysis must be considered.
First, the estimation of the Weibull parameters of PFS for the
subgroups of age and surgery type was an inevitable limitation.
The Weibull parameters of PFS determined the survival rates of
the disease-free patients. However, the results of the comparison of
the median PFS times between the model and the trial in the
MGMT subgroups indicates that the estimation method used in
this study minimized this bias. Second, because few head-to-head
trials have been conducted for the three first-line strategies for
GBM, an indirect comparison was used in this study. Similar
patient characteristics for the three strategies were assumed in our
indirect comparison, and the results of the indirect comparison
were imputed into the analytical model. When there is no direct
comparison trial, indirect comparisons using well-recognized
methods have been accepted by many researchers around the
world. When direct comparison data are available, this analysis
could be updated. Third, we did not fully explore other
therapeutic strategies for first- and second-line treatments of
GBM, especially targeted therapies such as bevacizumab [23,24],
Figure 5. The cost-effectiveness acceptability curves for the three first-line strategies for GBM in the overall cohort and the 8
subgroups. The vertical axes represent the probabilities of cost effectiveness. The horizontal axes represent the willingness-to-pay thresholds to
gain 1 additional quality-adjusted life-year (QALY). The bold vertical dashed and solid lines represent the thresholds for China and Shanghai City,
respectively.
doi:10.1371/journal.pone.0034588.g005
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a strategy is able to prolong the PFS time, the cost of the second-
line treatment will be reduced. Because the targeted therapies are
considered in the second-line treatment, the ICER of the TMZ
strategies could be improved. Fourth, the choice of the Chinese
healthcare system as our baseline perspective was narrow; as a
result, only the direct medical costs were estimated in the analysis.
An overall societal perspective that encompasses the indirect costs
of the disease, such as the burden on the families and caregivers,
may expand the costs associated with GBM. As such, oral
medications (e.g., TMZ) and prolonged PFS (e.g., TMZ) may
produce more favorable results. However, there is no well-
established method for incorporating such indirect costs into the
analysis when measuring the cost effectiveness of first-line
therapies for GBM. Finally, utility values were derived from
literature published abroad because of the absence of Chinese data
on this issue. However, we believe that this analysis can provide
helpful information for Chinese health policy decision-makers
because the results of this analysis reflect the general practice for
treating newly diagnosed GBM in China.
In conclusion, in the Chinese healthcare setting (which is
representative of a health resource-limited region), the addition of
TMZ to radiotherapy in patients with GBM would not be a cost-
effective approach compared to radiotherapy alone or radiother-
apy plus nitrosourea agents. However, better economic outcomes
are likely to occur when subgroups with more favorable prognostic
factors receive TMZ. Decreasing the price of TMZ might be one
potential way to counter the restrictive Chinese reimbursement
policies.
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